The present study was carried on forty (40) diagnosed ALL (Acute lymphoblastic leukemia), CML (Chronic myeloid leukemia), AML(Acute myeloid leukemia)patients who attended Oncology Centre, Mansoura University. Their ages ranged from 3 to 77 years. They were 27 males and 13 female. Patients were followed up throughout the period of the study. All patients were subjected to the following: Detailed history, clinical examination and Laboratory investigations. Results: CD04 expression was not associated with any of the studied demographic ,clinical or laboratory variables. No statistically significant associations were elicited between CD 04 expression and any of the studied prognostic factors of patients. However ,a significant positive association was detected between patients who responded to chemotherapy and positive CD04L. Conclusion: CD04L is an independent prognostic factor for relapse free survival ,and also an independent prognostic factor for the prediction of good response to chemotherapy ,since CD04L positive patients are more liable to achieve complete remission ,while CD 04 negative ones are more susceptible to death chemotherapeutic resistance.
INTRODUCTION
Leukemia are clonal , neoplastic proliferation of immature cells of the hematopoietic system, which are characterized by aberrant or arrested differentiation to increase in the number of blast cells that have common characteristics which induce poor responsiveness to regulatory mechanisms (apoptosis) and tendency to have diminished capacity for normal differentiation and expansion at the expense of normal elements 1 . CD40 is a 50-kDa cell surface protein, CD40 is best appreciated as a critical regulator of cellular and humoral immunity via its expression on B lymphocytes, dendritic cells, and monocytes 2 .
Aim of the work:
The aim of this work is to assess CD40L in patients with acute lymphoblastic leukemia , acute myeloid leukemia and chronic myeloid leukemia to evaluate its correlation with the different clinical and laboratory data as well as its relation to disease outcome and prognosis during the period of the study.
MATERIALS AND METHODS
The present study included serum samples from 40 patients, 14 (35%) with ALL, 20 (50%) with AML and 6 (15%) with CML.This cohort comprised 12 males and 28 females with a mean (±SD) age of 34.7 (±22.1) years. In addition, 10 healthy individuals were included as controls. All patients were subjected to: a) Detailed history b) Thorough clinical examination c) Laboratory investigations:
1-Complete blood count (CBC Assay procedure:
this test kit will supply one original Standard reagent, please dilute it by yourself according to the instruction 2.The quantity of the plates depends on the quantities of to-be-tested samples and the standards. It is suggested to duplicate each standard and blank well. Every sample shall be made according to your required quantity, and try to use the duplicated well as possible.
Inject sample: ① Blank well: don't add samples and sCD40L -antibody labeled with biotin, Streptavidin-HRP, only Chromogen solution A andB, and stop solution are allowed; other operations are the same. ② Standard wells: add standard 50μl, Streptavidin-HRP 50μl(since the standard already has combined biotin antibody, it is not necessary to add the antibody); ③ To be test wells: add sample 40μl, and then add both sCD40L-antibody 10μl and Streptavidin-HRP 50μl. Then seal the sealing memberance, and gently shaking, incubated 60 minutes at 37 ℃. Some investigated parameters were entered into a logistic regression model to determine which of these factors is considered as a significant risk factor and identify its odds ratio. Univaraite and multivariate survival analyses were performed with the Cox proportional hazards model. Survival curves were constructed according to the Kaplan-Meier method. Finally, a log-rank test was performed to evaluate the statistical significance of differences in survival
RESULTS
The present study included serum samples from 40 patients, 14 (35%) with ALL, 20 (50%) with AML and 6 (15%) with CML as shown in table(3). This cohort comprised 12 males and 28 females with a mean (±SD) age of 34.7 (±22.1)years. In addition, 10 healthy individuals were included as controls as shown in table(2). Serum levels of CD40L were determined by ELISA. Here, we demonstrated that a proportion of patients with ALL, AML or CML malignancies had significantly (P<0.001) elevated levels (Median =3.70) of the circulating soluble form of CD40Lin comparison with those of controls (Median =1.10). There was no significant difference (P =0.34) in CD40L levels between different types of leukemias as shown in table(1). Using 3.7 ng/ml as cutoff level, the prognostic value of CD40L was evaluated by comparing the overall survival of the CD40L Low group (<3.7ng/ml) with that of the CD40L High group (>3.7ng/ml). Patients in theCD40L
High group had a significantly shorter survival (P =0.009) than patients in the CD40L
Low group.In univariate analysis, other variables that were associated significantly with survival were blast cell count (P =0.034) and remission (P =0.003). The independence of the prognostic value of CD40L levels was evaluated by using the multivariate Cox regression model. Among all tested prognostic factors, only the level of CD40L (CD40L High vs. CD40L Low ) was a significant independent prognostic factor in this model (P<0.033) with high hazard ratio (4.224; 95% CI (1.121-15.923) as shown in table(15). Elevated levels were associated with significantly shorter treatment free and overall survival as shown in tables (13, 14) . There is no significant difference in CD40L serum levels between patients with normal liver and those with enlarged liver (P =0.22). Similarly, there is no significant difference in CD40L levels between patients with normal, large or removed spleen (P =0.25)as shown in 6 reported that freshly isolated B cells from a subset of chronic leukemiacases constitutively express CD40L, a member of the tumor necrosis factor family which is normally expressed by activated CD4(+) T cells and mediates T-cell-dependent B-cell proliferation and antibody production.
CD40L was detected in purified chronic leukemiaB cells by immunofluorescence flow cytometry, by RT-PCR, and by immunoprecipitation. To demonstrate that CD40L in the CLL B cells is functional, they used irradiated chronic leukemiacells to stimulate IgG production by target, nonmalignant B cells in coculture. The chronic leukemiaB cells induced IgG production by normal B cells to a similar degree as did purified T cells in a process which was partially inhibited by monoclonal antibody to CD40L 6 . Using 3.7 ng/ml as cutoff level, the prognostic value of CD40L was evaluated by comparing the overall survival of the CD40L Low group (<3.7ng/ml) with that of the CD40L High group (>3.7ng/ml). Patients in theCD40L
High group had a significantly shorter survival (P =0.009) than patients in the CD40L Low group.In univariate analysis, other variables that were associated significantly with survival were blast cell count (P =0.034) and remission (P =0.003). The independence of the prognostic value of CD40L levels was evaluated by using the multivariate Cox regression model. Among all tested prognostic factors, only the level of CD40L (CD40L High vs. CD40L Low ) was asignificant independent prognostic factor in this model (P<0.033) with high hazard ratio (4.224; 95% CI (1.121-15.923)).
Themajority of chronic leukemia cells strongly express membrane CD40 (mCD40), and mCD40-CD40L engagement within the lymph node microenvironment is thought to provide signals critical for their proliferation and survival 3 .It has become evident that high levels of proliferation of the leukemic population in chronic leukemiaare correlated with worse prognosis. In proliferation centers, chronic leukemiacells are in close contact with activated CD40L+ CD4+ T cells, and it has been proposed that these cells can support the growth of chronic leukemiacells through CD40 ligation.However, although CD40L stimulation alters the apoptotic profile of chronic leukemiacells and increases their resistance to apoptosis, it induces minimal proliferation on its own.Thus, there might be other stimuli provided by activated CD4+ T cells that contribute to proliferation of chronic leukemiacells 7 . So, increased levels of CD40L may cause in shorter survival.
Hock et al. 8
reported thatmany patients with hematologic malignancies have elevated circulating levels of soluble CD40, and these elevated levels are associated with a poor prognosis especially in patients with multiple myelomaand acute myeloid leukemia, suggesting that CD40 may have a role in modulating antitumor responses and also may 323 be a useful prognostic marker.Moreover, Hock et al.
3 investigated the prognostic significance of plasma CD40 in untreated chronic leukemiapatients. They reported that most of patients had levels higher than those of normal donors and that elevated levels were associated with significantly shorter treatment free and overall survival. These results suggestedthat CD40 may play a role in chronic leukemiaprogression.
Serum CD40L levels not correlate with some established prognostic factors like age, hemoglobin or platelet counts. Similar findings were obtained by Lee et al.
9 who reported that plasma CD40L levels not correlated with these parameters in sickle cell anemia. Else, theprognostic value of CD40L levels in ALL, AML and CML appears to be independent of other established prognostic factors like spleen and liver size.
There is no significant difference in CD40L serum levels between patients with normal liver and those with enlarged liver (P =0.22). Similarly, there is no significant difference in CD40L levels between patients with normal, large or removed spleen (P =0.25). These results suggest that, irrespective of its actual functional roles, CD40L merits further investigation as a clinically useful prognostic marker not only in ALL, AML and CML but also in chronic lymphatic leukemia 8 . Moreover, CD40L serum levels significantly (P<0.0001) correlated (r =0.606) with blast cell count. Else, CD40L levels significantly correlated with WBC count as another marker of inflammation. Similar correlation between CD40L and WBC was obtained by Uneket al. 10 .
CONCLUSION
The data presented in the current study demonstrate that significantly elevated levels of a circulating, soluble form of CD40L are present in patients with ALL, AML and CML malignancies and are associated with poor prognosisandshorter survival. Recommendation,these results further suggest that CD40Lis a potential prognostic biomarker for different types of leukemiamalignancies. Thus, we can recommend the detection of soluble CD40Las individual or in a combination with other established prognostic markers tonot only provides useful information for therapeutic supervision judgment but also to monitoring the disease. There is high significant difference between leukemia cases and controlCases. There is significance difference in CD40L levels between cases with remission and those who are relapsing. The serum level of CD40L was a significant independent prognostic factor. 
